BravoVax, a Wuhan vaccine developer, signed a letter of intent with Atlanta’s GeoVax Labs to jointly develop a coronavirus (2019-nCoV) vaccine. GeoVax will use its MVA-VLP vaccine platform to design and construct the candidate using genetic sequences from the coronavirus outbreak in Wuhan. BravoVax will provide testing and manufacturing support, and it will be responsible for interacting with China public health and regulatory authorities. A preclinical company, BravoVax is developing vaccines for pneumonia, respiratory syncytial virus, human papillomavirus and varicella zoster.
Source: China Biotoday
